Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Self-adjusting technology approved for ages 2 and older.* Now with smartphone connectivity.
LEARN MOREThe new MiniMed™ 770G system automatically adjusts insulin levels and takes on more of the tasks of managing diabetes so your patients can focus more on their daily lives.*
Refers to SmartGuard™ Auto Mode. Some user interaction required. Individual results may vary.
Any customer using the MiniMedTM 770G system will get access to our next technology, when available, at no cost through October 27, 2022.† Our next innovation goal is to reduce fingersticks and bring you an advanced algorithm with auto-correction bolus for easier mealtimes. Get access to the future by filling out the form below and learning more about the MiniMedTM 770G system.
Click here to learn about our future innovations.
Refers to SmartGuard™ Auto Mode. Some user interaction required. Individual results may vary.
The MiniMed™ 770G system with Bluetooth® connectivity enables automatic CareLink™ uploads, helping support meaningful conversations with your patients, whether in-person or via telehealth.
Your patients can now use their smartphones to view their data. This means they can easily and discreetly track their glucose levels and get notified of highs and lows.
Available for care partners, this app helps keep everyone in the loop. Up to five care partners can now follow a pump user and receive high and low notifications.
CareLinkTM Patient Representative Profile
Refers to SmartGuard™ Auto Mode. Some user interaction required. Individual results may vary.
Software Upgrade Terms and Conditions
Important Safety Information: MiniMedTM 770G System with SmartGuardTM Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G system consists of the following devices: MiniMed™ 770G insulin pump, the Guardian™ Link (3) transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu-Chek® Guide test strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.”
©2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.